End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
179,700 KRW | +0.56% | +4.48% | -10.82% |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Apr. 17 | Celltrion, Inc. authorizes a Buyback Plan. | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 71.98 and 33.45 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.82% | 26.87B | C | ||
+3.13% | 42.11B | B | ||
+48.83% | 40.08B | A | ||
+8.49% | 40B | B- | ||
+8.26% | 24.58B | B- | ||
-23.69% | 18.44B | B | ||
+1.58% | 11.94B | C+ | ||
+32.83% | 11.66B | C+ | ||
+6.63% | 11.01B | B+ | ||
-17.46% | 9.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A068270 Stock
- Ratings Celltrion, Inc.